Therefore, we have carried out this study to examine the expression of RhoT1, Smad4 and p16 in pancreatic cancer, and to analyze whether the expression patterns of RhoT1, Smad4 and p16 are correlated with metastatic potential and are predictive of clinical outcome in patients with pancreatic cancer. Here, SMAD4 is linked to pancreatic neoplasm.